ZOM Stock Price: Zomedica Corp extends rally following year end 2020 results
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- NYSEAMERICAN:ZOM gained a further 2.91% on Tuesday despite the border market retreat.
- Zomedica reported its Q4 and year end 2020 earnings results on Friday after the closing bell.
- Investors continue to believe that the impending Truforma release will launch Zomedica to a huge windfall.
NYSEAMERICAN:ZOM continued its stellar year ever since the calendar flipped to 2021, as the pet diagnostic company is still up over 500% year to date. Tuesday saw Zomedica continue its momentum from Monday as the stock gained 2.91% to close the trading session at $2.12. It has been less than a year since Zomedica was trading as a penny stock as is evident by its 52-week low price of $0.06. In the meantime, Zomedica briefly rode the wave of being a target of the Reddit sugroup r/WallStreetBets which accounted for much of the rise in the stock’s price.
Stay up to speed with hot stocks' news!
On Friday, Zomedica released its Q4 and year end 2020 financial results, and the news was somewhat optimistic for a company that has zero revenues to date. Losses were lower year-over-year from 2019, as ZOM announced losses of $16.9 million in 2020 compared to $19.8 million in 2019. This equates to roughly losses of $0.05 per share compared to $0.19 per share in 2019. Zomedic also reported it had nearly $280 million in the bank after several rounds of stock offerings to raise cash and take advantage of its current stock price.
ZOM stock forecast
Of course, the main focus for Zomedica investors continues to be the upcoming release of its Truforma pet diagnostic platform at the end of March. While a nationwide rollout does not seem to be in the cards, Zomedica is taking its time with a staggered, regional rollout, which should help keep costs lower, but at the same time, limit the rate of sales growth.
- NYSEAMERICAN:ZOM gained a further 2.91% on Tuesday despite the border market retreat.
- Zomedica reported its Q4 and year end 2020 earnings results on Friday after the closing bell.
- Investors continue to believe that the impending Truforma release will launch Zomedica to a huge windfall.
NYSEAMERICAN:ZOM continued its stellar year ever since the calendar flipped to 2021, as the pet diagnostic company is still up over 500% year to date. Tuesday saw Zomedica continue its momentum from Monday as the stock gained 2.91% to close the trading session at $2.12. It has been less than a year since Zomedica was trading as a penny stock as is evident by its 52-week low price of $0.06. In the meantime, Zomedica briefly rode the wave of being a target of the Reddit sugroup r/WallStreetBets which accounted for much of the rise in the stock’s price.
Stay up to speed with hot stocks' news!
On Friday, Zomedica released its Q4 and year end 2020 financial results, and the news was somewhat optimistic for a company that has zero revenues to date. Losses were lower year-over-year from 2019, as ZOM announced losses of $16.9 million in 2020 compared to $19.8 million in 2019. This equates to roughly losses of $0.05 per share compared to $0.19 per share in 2019. Zomedic also reported it had nearly $280 million in the bank after several rounds of stock offerings to raise cash and take advantage of its current stock price.
ZOM stock forecast
Of course, the main focus for Zomedica investors continues to be the upcoming release of its Truforma pet diagnostic platform at the end of March. While a nationwide rollout does not seem to be in the cards, Zomedica is taking its time with a staggered, regional rollout, which should help keep costs lower, but at the same time, limit the rate of sales growth.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.